PhilippeSzaparyMDMSCE

Cardiology

Vice President, Immunology Clinical Development at Janssen, Pharmaceutical Companies of Johnson and Johnson. Preventative Cardiology

Dr. Szapary is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
3400 Civic Center Blvd
# E
Philadelphia, PA 19104
Phone+1 215-615-4949

University of California (San Francisco)Residency, Internal Medicine, 1994 - 1997
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1994

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

PubMed

4 citations
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease.
Jason J Luke, Diwakar Davar, Robert H Andtbacka, Nina Bhardwaj, Joshua D Brody
Journal for Immunotherapy of Cancer. 2024-04-18
Reply.
Anil Vachani, Meijia Zhou, Sudip Ghosh, Shumin Zhang, Philippe Szapary
Journal of the American College of Radiology. 2024-04-01
8 citations
The Effect of Definitions and Cancer Prevalence on Diagnostic Yield Estimates of Bronchoscopy: A Simulation-based Analysis.
Anil Vachani, Fabien Maldonado, Balaji Laxmanan, Meijia Zhou, Iftekhar Kalsekar
Annals of the American Thoracic Society. 2023-10-01

Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development ProgramsFebruary 9th, 2019
De Nouvelles Données De Phase 3 Montrent Qu'une Dose Unique De STELARAOctober 10th, 2018
New Phase 3 Data Show Single Dose of STELARAOctober 9th, 2018
Join now to see all